摘要
目的 探讨弥漫大B细胞淋巴瘤(DLBCL)中KLF13的表达水平及其意义.方法 对56例行CHOP方案化疗的DLBCL患者随访4~6年;采用免疫组织化学方法检测患者组织标本中KLF13的表达水平,分析KLF13表达与DLBCL患者生存率、临床特征之间的关系;采用Western blot法检测DLBCL细胞株Pfeiffer、LY8中KLF13表达水平.应用siRNA阻断DLBCL细胞内KLF13表达后,采用CCK-8方法检测DLBCL细胞的增殖水平.结果 32例(57.1%) DLBCL患者KLF13高表达,24例(42.9%)低表达.KLF13高表达组5年生存率(46.5%)低于低表达组(75.0%)(P=0.01).多因素Cox回归分析结果表明,KLF13蛋白表达水平、血清LDH水平和临床病理分期是影响患者预后的独立因素(均P< 0.05).KLF13表达高低与DLBCL患者的临床分期、淋巴结直径相关;阻断DLBCL细胞KLF13表达后,细胞增殖水平降低.结论 KLF13可作为DLBCL的预后预测因子及治疗靶点.
Objective To investigate the expression level and its significance of KLF13 in patients with diffuse large B-cell lymphoma (DLBCL).Methods Fifty-six DLBCL patients treated with CHOP chemotherapy regimen were followed up in 4-6 years.Tissue samples of the 56 DLBCL patients were collected.Then the expression level of KLF13 in tissue samples was detected by immunohistochemistry,the relationship between the expression level of KLF13 and the survival rate,clinical features of the patients were analyzed,respectively.Western blot was used to detect the expression level of KLF13 in DLBCL cell trains Pfeiffer and LY8.Subsequently,the expression of KLF13 in DLBCL cell strains was blocked by siRNA method.The proliferation rates of DLBCL cell strains were assayed by CCK-8.Results The expression of KLF13 was significantly over-increased in 32 patients with DLBCL (57.1%) and slightly increased in 24 patients with DLBCL (42.9 %).The 5-year survival rate in the significant overexpression group (46.5 %) was lower than that of slight overexpression group (75.0 %) (P =0.01).Multivariate analysis demonstrated that KLF13 expression,serum LDH levels and clinical pathological stage were independent prognostic indicators for patients with DLBCL (all P 〈 0.05).There was statistically significant association between the expression level of KLF13 and the clinical stage,the diameter of lymphoma,respectively.After the expression of KLF13 in DLBCL cells was blocked,the proliferation rate of cells decreased.Conclusion KLF13 might be regarded as a prognostic factor and used as a treatment target.
出处
《白血病.淋巴瘤》
CAS
2013年第7期439-443,共5页
Journal of Leukemia & Lymphoma